Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Lexaria Bioscience Corp (NASDAQ: LEXX) was $0.67 for the day, up 15.69% from the previous closing price of $0.58. In other words, the price has increased by $15.69 from its previous closing price. On the day, 0.85 million shares were traded. LEXX stock price reached its highest trading level at $0.6998 during the session, while it also had its lowest trading level at $0.55.
Ratios:
Our analysis of LEXX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.32 and its Current Ratio is at 2.32. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 29 ’25 when BUNKA CHRISTOPHER bought 15,600 shares for $0.92 per share. The transaction valued at 14,375 led to the insider holds 270,012 shares of the business.
BUNKA CHRISTOPHER bought 11,900 shares of LEXX for $10,866 on Jul 30 ’25. The Director now owns 281,912 shares after completing the transaction at $0.91 per share. On Jul 29 ’25, another insider, McKechnie William Edward, who serves as the Director of the company, bought 5,000 shares for $0.91 each. As a result, the insider paid 4,532 and bolstered with 18,191 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LEXX now has a Market Capitalization of 16774141 and an Enterprise Value of 12735115. For the stock, the TTM Price-to-Sale (P/S) ratio is 23.62 while its Price-to-Book (P/B) ratio in mrq is 4.41. Its current Enterprise Value per Revenue stands at 18.04 whereas that against EBITDA is -1.103.
Stock Price History:
The Beta on a monthly basis for LEXX is 0.63, which has changed by -0.7361991 over the last 52 weeks, in comparison to a change of 0.13153219 over the same period for the S&P500. Over the past 52 weeks, LEXX has reached a high of $2.43, while it has fallen to a 52-week low of $0.48. The 50-Day Moving Average of the stock is -32.68%, while the 200-Day Moving Average is calculated to be -37.40%.
Shares Statistics:
LEXX traded an average of 627.12K shares per day over the past three months and 636550 shares per day over the past ten days. A total of 24.89M shares are outstanding, with a floating share count of 23.39M. Insiders hold about 6.00% of the company’s shares, while institutions hold 6.90% stake in the company. Shares short for LEXX as of 1764288000 were 605052 with a Short Ratio of 0.96, compared to 1761868800 on 741082. Therefore, it implies a Short% of Shares Outstanding of 605052 and a Short% of Float of 2.8399997999999997.
Earnings Estimates
At present, 2.0 analysts are actively evaluating the performance of Lexaria Bioscience Corp (LEXX) in the stock market.The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.14 and low estimates of -$0.16.
Analysts are recommending an EPS of between -$0.34 and -$0.68 for the fiscal current year, implying an average EPS of -$0.52. EPS for the following year is -$0.75, with 2.0 analysts recommending between -$0.33 and -$1.17.
